Key result
Early alteplase is linked to significantly better neurologic and functional recovery vs delayed aspirin.
Why the study?
Timely treatment with thrombolytic agents like alteplase and antiplatelet drugs such as aspirin can improve clinical outcomes in ischemic stroke, but comparative therapeutic outcomes remain to be clarified.
Does alteplase administered within 3 hours of symptom onset improve clinical outcomes compared to aspirin administered after 12 hours in patients with ischemic stroke?
Cohort
No
Does alteplase administered within 3 hours of symptom onset improve clinical outcomes compared to aspirin administered after 12 hours in patients with ischemic stroke?
Answers are grounded in this paper and cite their sources.
Alteplase administered within 3 hours of ischemic stroke onset significantly improves clinical and functional outcomes compared to late aspirin administration, though with a higher risk of intracranial hemorrhage.
Background and Aim: Stroke is one of the most common causes of disability and mortality worldwide, with ischemic stroke accounting for the majority of cases.Timely treatment with thrombolytic agents like alteplase and antiplatelet drugs such as aspirin can improve clinical outcomes.This study aimed to compare the therapeutic outcomes of alteplase and aspirin in patients with ischemic stroke. Materials and Methods:This analytical cross-sectional and prospective cohort study was conducted at Shahid Beheshti Hospital in Kashan in 2023.Patients were divided into two groups based on the time of hospital arrival and NIHSS scores: The alteplase group (treatment within 3 hours of symptom onset) and the aspirin group (treatment after 12 hours).Demographic, clinical, and laboratory variables, as well as treatment outcomes (NIHSS and MRS scores), were compared at 72 hours and 90 days post-treatment.Data were analyzed using SPSS software, version 22 and appropriate statistical tests.Results: The mean age of patients was 59.3±8.22 years in the alteplase group and 57.7±6.6 years in the aspirin group.Significant improvement in NIHSS and MRS scores was observed in both groups, but the alteplase group showed greater improvement at both 72 hours and 90 days posttreatment (P=0.001).Mortality rates did not differ significantly between the groups, but adverse effects such as intracranial hemorrhage were more frequent in the alteplase group.Conclusion: Treatment with alteplase compared to aspirin can lead to significant improvement in clinical outcomes for ischemic stroke patients, particularly when administered within the 3-to 4.5-hour window after symptom onset.However, careful management of adverse effects, such as intracranial hemorrhage, is essential.Increasing public awareness about the importance of timely hospital admission can enhance the efficacy of thrombolytic therapies.
No takes yet. Share an insight, caveat, or question.
kouchaki et al. (2024) conducted a cohort in Ischemic stroke. Alteplase vs. Aspirin was evaluated on NIHSS and MRS scores at 72 hours and 90 days post-treatment (p=0.001). Alteplase administered within 3 hours of symptom onset resulted in greater improvement in NIHSS and MRS scores at 72 hours and 90 days compared to aspirin.
Synapse has enriched 10 related papers. Consider them for comparative context: